ClinicalTrials.gg
Active, not recruitingNCT06247280Updated Dec 6, 2024

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

An observational study in NSCLC, sponsored by Yuhan Corporation. Active, not recruiting at 39 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Yuhan Corporation · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
2,001
Ages
20 Years and older
Sex
All
01

Study summary

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.

Read the detailed description

The Korean EGFR Registry is a prospective multicenter observational cohort study designed to enroll all stage EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, due to the extended follow-up period required to confirm clinical outcomes, a retrospective cohort has been included. This retrospective cohort comprises patients with recurrent or metastatic NSCLC who began taking EGFR TKI after January 2021. The recruitment phase was planned to span 36 months, commencing in May 2022, with scheduled follow-up activities continuing until December 2026. The target enrollment for this study is set at 2,000 patients, with competitive enrollment to be carried out across 40 university hospitals in Korea.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with non-small cell lung cancer of any stage with an EGFR mutation newly diagnosed after the date of IRB approval, or patients who started EGFR-targeted therapy for the first time after 2021-01-01 with metastatic or recurrent EGFR mutation non-small cell lung cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults over 20-year-old with Korean nationality
  2. A person who voluntarily signed the form for this study
  3. All stage Non small cell lung cancer patients with EGFR mutation or or recurred EGFR mutated NSCLC patients started with EGFR TKI treatment from 2021-01-01.

Exclusion criteria

Exclusion Criteria:

  1. A person who is not confirmed NSCLC histologically or cytologically.
  2. A person who doesn't consent to the study.
  3. A person who is unable to complete the study judged by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
2,001 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Clinical characteristics of NSCLC patients with EGFR mutation

    Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation

    Time frame: 12months, 18months, 24months, 36months

  2. Clinical outcome of NSCLS patients with EGFR mutation

    Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation

    Time frame: 12months, 18months, 24months, 36months

  3. PFS

    PFS underwent palliative therapy according to stages in NSCLC patients with EGFR mutation

    Time frame: 12months, 18months, 24months, 36months

  4. DFS

    DFS in patients underwent definitive therapy according to stages in NSCLC patients with EGFR mutation

    Time frame: 12months, 18months, 24months, 36months

Secondary outcomes

  1. Diagnosis Test Method

    Frequency of diagnostic test methods according various clinical samples

    Time frame: up to 36months

  2. Diagnosis Test Method

    Proportion of diagnostic test methods according various clinical samples

    Time frame: up to 36months

  3. OS(Overall survival)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  4. ORR(overall response rate)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  5. DoR (duration of response)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  6. DCR (disease control rate)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  7. TTF (time to treatment failure)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  8. TTNF (time to next treatment)

    Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  9. Analysis of metastatic sites and treatment patterns (especially brain and bone metastasis)

    Exploration of clinical characteristics and metastatic patterns in NSCLC patients with EGFR mutation

    Time frame: up to 36months

  10. Adverse event profiles

    Adverse event profiles after lazertinib administration

    Time frame: up to 36months

07

Study locations

39 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2024
First posted
Feb 7, 2024
StartActual
Jun 24, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06247280
Lead sponsor
Yuhan Corporation
Collaborators
The Korean Academy of Tuberculosis and Respiratory Diseases
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Jun 24, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 6, 2024

Study contacts

Sae Young Lee
study director · Yuhan Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion